Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
RXRX · against 454 other Healthcare companies listed in US-listed
Ranked #393 of 455 · scores higher than 13% of peers
Bars: peers in each 10-point band of the growth score26 peers with a growth score of 10–19, including RXRX · Click a bar to see the companies
Mainly because of its revenue growth and 3-year revenue growth, which are weaker than most Healthcare peers.
| Metric | RXRX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 475 reported | -15.1% | 11.0% | 13% | 33% | |
| Earnings per share growthHigher is better · 171 reported | Not reported | 21.2% | — | — | 33% |
| 3-year revenue growthHigher is better · 433 reported | 3.1% | 11.0% | 28% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 460M USD | 100 | 53 | |
| 2 | 1.4B USD | 99 | 73 | |
| 2 | 441M USD | 99 | 81 | |
| 2 | 9.5B USD | 99 | 31 | |
| 2 | 87M USD | 99 | 27 | |
| 388 | 1.6B USD | 18 | 30 | |
| 388 | 552M USD |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score
| 58 |
| 393 | 220M USD | 17 | 10 |
| 393 | 15.2B USD | 17 | 33 |
| 393 | 2.1B USD | 17 | 24 |
| 396 | 596M USD | 16 | 31 |
| 396 | 243M USD | 16 | 38 |
| 398 | 599M USD | 15 | 34 |
| 398 | 3.6B USD | 15 | 43 |